Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Alessandro PassardiIrene AzzaliAlessandro BittoniGiorgia MarisiFrancesca RebuzziChiara MolinariGiulia BartoliniLaura MatteucciFrancesco Giulio SulloSilvia Angela DebonisChiara GallioManlio MontiMartina ValgiustiMargherita MuratoreIlario Giovanni RapposelliPaola UliviGiovanni Luca FrassinetiPublished in: Therapeutic advances in medical oncology (2023)
Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC.